Recent developments in the drug treatment of motor neurone diseaseBMJ 1994; 309 doi: http://dx.doi.org/10.1136/bmj.309.6948.140 (Published 16 July 1994) Cite this as: BMJ 1994;309:140
- R W Orrell,
- R J M Lane,
- R J Guiloff
Motor neurone disease is a progressive degenerative disease of motor neurones leading to incapacitating neurological disability and death in over 1000 adults in Britain each year. About 5% of cases are familial; no specific treatment exists. The average length of survival from the onset of symptoms is only three years.
A recently reported controlled trial of riluzole, which inhibits release of glutamate,1 in the treatment of motor neurone disease (known as amyotrophic lateral sclerosis in the United States) raised patients' hopes. It concluded that riluzole slightly slowed the fall in muscle strength and increased survival at one year in a small subgroup of patients.2 Unfortunately, the overall results are not convincing of a significant benefit on a number of statistical and methodological grounds, and the findings of a larger, international trial are awaited.
The precise cause of motor neurone disease remains unknown. Excitotoxicity, oxidative stress, growth factors, and immunological abnormalities have all been included in pathogenetic theories, and current therapeutic trials are based on these concepts. The excitotoxic theory proposes that excess excitatory neurotransmitters, especially glutamate, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial